Taipei Medical University
Taipei, 110, Taiwan
Location status: Recruiting
NCT Number: NCT07172607
This study aims to examine the effectiveness of Avance eZZe drink with liposomal technology in improving sleep quality. Participants will be randomly assigned to either the placebo group, Avance eZZe drink group, and Avance eZZe drink without liposomal group, with 25 participants in each group. On the day of the experiment (day 0), participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them 1 hour before sleep daily for 28 days. Follow-up assessments will be conducted in the day-1, day-14 and day-28, participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Taipei, 110, Taiwan
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
Time frame: Day-0 (baseline), Day-1, Day-14, Day-28
The difference of electrocardiosignal between two specific points on the body surface will be used to reflect sleep state.
Time frame: Day-0 (baseline), Day-14, Day-28
The Pittsburgh Sleep Quality Index (PSQI) will be utilized to assess sleeping quality. The minimum value is 0, the maximum value is 42. The higher the score, the worse the outcome.
Time frame: Day-0 (baseline), Day-14, Day-28
The Insomnia Severity Index (ISI) will be utilized to assess insomnia severity. The total score ranges from 0 to 28, with higher scores indicating more severe insomnia.
Time frame: Day-0 (baseline), Day-14, Day-28
The Epworth Sleepiness Scale (ESS) will be utilized to assess the general level of daytime sleepiness. The total score ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.
Time frame: Day-0 (baseline), Day-14, Day-28
Patient Health Questionnaire-9 (PHQ-9) will be utilized to assess depression level. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.
Time frame: Day-0 (baseline), Day-14, Day-28
Generalized Anxiety Disorder-7 (GAD-7) will be utilized to assess anxiety level. The total score ranges from 0 to 21, with higher scores indicating greater anxiety severity.
Time frame: Day-0 (Baseline), Day-1, Day-14, Day-28
A sleep monitoring system will be utilized to measure LF/HF ratio.
Contact information is provided by the study sponsor or research team.
TCI Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07444372
Apnea, Arrhythmia
Beijing, Beijing Municipality, China
View Trial DetailsNCT07573488
Behavior, Brain Diseases
Zurich, Switzerland
View Trial DetailsNCT07315516
Anxiety, Anxiety Disorders
Brisbane, Australia
View Trial DetailsNCT07210476
Chronic Conditions, Chronic Disease
Istanbul, Turkey (Türkiye)
View Trial Details